RxDoctor Payments DataLook up a doctor →

Dallas Bondhus, PA

Medical · Hot Springs, ARNPI 1205826187

Payments from drug & device makers

$15,495in general payments, 2019–2025

Across 836 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • EMD Serono, Inc.$1K
  • MDD US Operations, LLC$1K
  • Biogen$1K
  • AstraZeneca$926
  • UCB, Inc.$809
  • plus $8K from 36 others

What the payments were for

  • Speaking & faculty fees$320%
  • Food & beverage$15,34699%
  • Education$1181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,495 in reported general payments places this provider in the 95th percentile of 133 medical providers in Arkansas.

See all medical providers in Arkansas

Medicare billing

Part B allowed, 2024
$81,576
Medicare patients
467
Services billed
1,564

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4618$369,983
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5017$313,764
Kesimpta PenOfatumumab27$274,336
AubagioTeriflunomide18$164,132
NuplazidPimavanserin Tartrate22$102,152
RytaryCarbidopa/Levodopa72$59,654
Aimovig AutoinjectorErenumab-Aooe28$28,473
Emgality PenGalcanezumab-Gnlm19$27,056
Emgality SyringeGalcanezumab-Gnlm14$25,823
Nurtec OdtRimegepant Sulfate15$25,533
UbrelvyUbrogepant11$19,721
XcopriCenobamate12$13,558
DepakoteDivalproex Sodium12$11,098
Ajovy AutoinjectorFremanezumab-Vfrm12$9,673
Carbidopa-LevodopaCarbidopa/Levodopa317$8,978

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$319$164,13218 claims
Acadia Pharmaceuticals IncNuplazid$148$102,15222 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$567$61,06792 claims
PfizerNurtec Odt, Dilantin$658$31,31540 claims
AbbVieUbrelvy$1,902$19,72111 claims
SK Life Science, Inc.Xcopri$592$13,55812 claims
Lilly USA, LLCReyvow$479$7,81311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 133 medical providers in Arkansas.

Other medical in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →